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Available online 24 November 2015Long term survival of childhood cancers is nowmore than 70%. Anthracyclines, including doxorubicin, are some
of the most efﬁcacious anticancer drugs available. However, its use as a chemotherapeutic agent is severely hin-
dered by its dose-limiting toxicities. Most notably observed is cardiotoxicity, but other organ systems are also de-
graded by doxorubicin use. Despite the years of its use and the amount of informationwritten about this drug, an
understanding of its cellularmechanisms is not fully appreciated. Themechanisms bywhich doxorubicin induces
cytotoxicity in target cancer cells have given insight about how the drug damages cardiomyocytes. The major
mechanisms of doxorubicin actions are thought to be as an oxidant generator and as an inhibitor of topoisomer-
ase 2. However, other signaling pathways are also invoked with signiﬁcant consequences for the cardiomyocyte.
Further the interaction between oxidant generation and topoisomerase function has only recently been appreci-
ated and the consequences of this interaction are still not fully understood. The unfortunate consequences of
doxorubicin within cardiomyocytes have promoted the search for new drugs and methods that can prevent or
reverse the damage caused to the heart after treatment in cancer patients. Alternative protocols have lessened
the impact on newly diagnosed cancer patients. However the years of doxorubicin use have generated a need
for monitoring the onset of cardiotoxicity as well as understanding its potential long-term consequences.
Although a fairly clear understanding of the short-term pathologic mechanisms of doxorubicin actions has
been achieved, the long-termmechanisms of doxorubicin induced heart failure remain to be carefully delineated.
© 2015 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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DNA damage1. Introduction
Long term survival of childhood cancers is nowmore than 70% [21].
Unfortunately, adult survivors of childhood cancer are at risk for a vari-
ety of treatment-related adverse health outcomes. Using clinical criteria,
survivors with a median time from diagnosis of 25 years [range 10–47
years] were assessed for the prevalence of adverse health outcomes.
Among them were abnormal pulmonary function (65.2%), auditory
(62.1%), endocrine conditions (62.0%), cardiac dysfunction (56.4%),
and neurocognitive impairment (48.0%), whereas abnormalities
involving hepatic dysfunction (13.0%), osteoporosis (9.6%), kidney dys-
function (5.0%) were less common [37,91]. Anthracyclines, including
doxorubicin, are some of the most efﬁcacious anticancer drugs available.
Their use has extended over 3 decades despite numerous side effects. The
studies of childhood survivors 4 to 20 years after doxorubicin treatment
observed signiﬁcant decreases in fractional shortening and ejection
fractions, and that was dependent upon the cumulative dose [2,30,31,
33,42,54,55,89,90]. Analysis of heart transplantation patients founddoxo-
rubicin as the underlying cause in 2–3% of all cases [7]. Several reviews
have been written that focus on the pathophysiology of doxorubicin, New York Medical College, 15
is an open access article under the Ccardiotoxicity for the patient [15,47,57,80,100]. This review will focus
more on the cellular and molecular impacts of doxorubicin on the heart
with purpose of more fully delineating the underlying molecular mecha-
nisms that promote cardiotoxicity.
2. Chemical structure
Doxorubicin, also known as Adriamycin® or Rubex®, is an
anthracycline antibiotic that was discovered from a mutated strain of
Streptomyces peucetius. Doxorubicin operates on several levels by differ-
entmolecularmechanisms including an interactionwith iron, upsetting
calcium homeostasis, altering the activity of intracellular or intra-
mitochondrial oxidant enzymes, and binding to topoisomerases pro-
moting their dysfunction (Fig. 1).
Doxorubicin consists of a naphthacenequinone nucleus and
daunosamine, an amino sugar. Doxorubicin has both hydrophilic and hy-
drophobic regions, allowing it to bind to plasma proteins as well as cell
membranes. Doxorubicin is also amphoteric; in having both acidic and
basic functions. It is these features thatmake doxorubicin a versatile com-
pound, allowing it to enter various cellular compartments. Doxorubicin
can be reduced intracellularly into doxorubicinol and this metabolite
also has biological activity [71]. Doxorubicin can also be reduced to a
semiquinone radical by many of the intracellular oxidoreductases. Re-
oxidation of this radical resulted in the production of reactive oxygenC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chemical structure of doxorubicin and its metabolite doxorubicinol. FromWang et.al. [103].
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tineoplastic and antibiotic capabilities. Excretion is through the liver and
kidney with a biphasic half life of 5 min and 30–40 h [43,78]. Alternative
forms of doxorubicin including liposomal-encapsulated forms have been
developed in an attempt to decreased cardiotoxicity. These forms do not
readily exit the vascular system but only in regions where the structures
may be disrupted by tumor growth and are likely to have less access to
the heart [54]. Various products including Doxil™, Myocet™ and
DaunoXome™ are all commercially available. Meta-analysis found that
although cardiotoxicity remained a function of cumulative dose, use of li-
posomal-encapsulated doxothracyclines lowered the incidence of
cardiotoxicity [75,94]. More recently, biodegradable microparticles or
nanoparticles containing doxorubicin have been explored as a slow re-
lease mechanism of doxorubicin therapy [59,63,76].
3. Detection and cardiotoxicity
The increased risk of cardiac dysfunction fromdoxorubicin canman-
ifest acutely during treatment or chronically weeks to years after treat-
ment has ceased. Cardiac dysfunction may present across a board
spectrum of symptoms that may range from arrhythmias to overt
heart failure. Several standard approaches of cardiology have been ap-
plied towards the detection of cardiotoxicity, including electrocardiog-
raphy, echocardiography, biopsy, scintigraphy, serum analysis, and
genomic markers. However, not all protocols have proven to be helpful.
Standard echocardiography provides visualization of heart structure
and can detect cardiac dysfunction via measures. Radionuclide based
tests, such as radionuclide angiocardiography and ventriculography,
when performed serially before, during, and after treatment are more
sensitive to changes in cardiac function [32]. More recently, the use of
radial strain has been studied. Strain is a measure of the deformation
of the myocardium that occurs during the cardiac cycle and is deter-
mined by the change in length of the tissue relative to its original length
[28,51]. Doxorubicin induced damage causes myocyte death and the in-
jured regions do not function as well as normal tissue resulting in
dyssynchrony and deformation. In both human and animal studies
two-dimensional strain echocardiography appeared more sensitive
than standard echocardiography protocols providing additional insight
into doxorubicin induced cardiac injury [36,65].
Serum biomarkers for cardiac injury more commonly used to detect
ischemia may also reﬂect acute doxorubicin-induced cardiomyopathy.
Although elevated circulating levels of cardiac troponin T have been re-
ported, the increases are not quantitatively consistent with the degree
of doxorubicin-induced cardiac injury [72,85]. Stronger correlations of
circulating brain-type natriuretic peptide to doxorubicin-induced cardi-
ac dysfunction have been demonstrated than with the atrial natriuretic
peptide [85]. Distinct from cardiac troponin T that indicate cardiomyo-
cyte damage, the natriuretic peptides reﬂect an early response to
cardiac insufﬁciency. More recently, the use of circulating genomic bio-
markers in monitoring and predicting doxorubicin-induced heart fail-
ure is also currently being investigated. These animal studies haveexamined changes in expression of microRNAs. Of the potential
markers, both miR-208 and miR-216B were responsive to doxorubicin
treatment and that miR-216B did appear dose-dependent responsive
to doxorubicin [70,98]. However, similar to radiolabeled antibodies ele-
vated circulating levels are only detectable as a following indicator to
myocyte damage.
Although used but not clinically practical, histopathological results
from endomyocardial biopsies are very sensitive in detection of late-
onset cardiotoxicity [72]. Alternatively, combination radiolabeled anti-
bodies with scintigraphy is also useful. Antimyosin antibodies bind
intracellularly to the heavy chain of myosin but can only do so when
cell membrane integrity is compromised, allowing for localization ex-
clusively to damaged cardiomyocytes. Carrió et al. demonstrated that
increased uptake of 111In labeled antimyosin in patients with sarcomas
being treated with doxorubicin was predictive of future progression of
cardiotoxicity [17]. Patients with higher uptake levels of the antibody
at intermediate cumulative doses of doxorubicin initially showed no si-
multaneous decline in left ventricular ejection fraction. However, as
treatment continued, these patients with previous high uptake levels
were more likely to develop cardiac dysfunction or mild congestive
heart failure as a result of increased cumulative exposure than those pa-
tients with lower uptake levels at the intermediate cumulative dose.
Valdés Olmos et al. investigated the sensitivity of 111In-antimyosin and
scintigraphy in detecting early cardiac injury in breast cancer patients
receiving low doses of doxorubicin [99]. After comparing measure-
ments ofmyocardial uptake of the antibody to other assessments of car-
diac dysfunction, such as left ventricular ejection fraction, it was
concluded that localization of 111In-antimyosin was representative of
myocyte injury, even at low cumulative doses of doxorubicin (120–
150 mg/m2). These ﬁndings suggest that progressive myocyte injury
precedes clinically signiﬁcant cardiac dysfunction, and use of this tech-
nique may help determine and individual patient's risk of developing
heart failure in response to increasing doses of doxorubicin. However,
there is little information about the usefulness of this marker in
predicting late-onset cardiotoxicity, which if accurate, could have a
major impact on the prevention of doxorubicin-induced congestive
heart failure, especially in survivors of childhood cancer.
Acute cardiotoxicity that may appear during treatment or shortly
thereafter presents with abnormal changes in heartbeat, which may or
may not be seen with non-speciﬁc ST-T wave changes in electrocardio-
grams [82,88,101]. Acute episodes have been reported to occur in up to
40% of patients given doxorubicin [50]. The occurrence of an acute
episode has not been predictive of late onset cardiac dysfunction [74].
Beyond the early effects, sub-acute cardiotoxicity may present with-
in a few weeks to a few months. These effects may be attributed to al-
tered Ca+2 dynamics, increased oxidative stress, or altered myocardial
energetics [23,26,68,71]. Delayed effects have been reported in studies
of childhood survivors 4 to 20 years after doxorubicin treatment
where signiﬁcant decreases in fractional shortening and ejection frac-
tions were observed [2,30,31,33,42,54,55,89,90]. There appears to be a
relationship between delayed development of congestive heart failure
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of 500 mg/m2, there was a 4% risk of congestive heart failure. However,
there is a rapid escalation in risk of congestive heart failure to 36% as cu-
mulative doses exceeded 600 mg/m2 [61].
While cumulative dose is the greatest risk factor for developing
doxorubicin- induced cardiotoxicity, several other factorsmay also con-
tribute to the likelihood of developing heart failure. Receipt of other
cardiotoxic chemotherapeutic drugs, such as trastuzumab or cyclophos-
phamide, signiﬁcantly increases the chance of cardiotoxicity. Patients
who received mediastinal radiation, a treatment for Hodgkin's lympho-
ma, had their own increased risk for cardiac dysfunction; this was in-
creased when received in combination doxorubicin [64]. One study
has suggested that gender may be signiﬁcant in that females treated
with doxorubicin are more likely to develop cardiac dysfunction [18].
Additionally, the younger a patient is when receiving treatment, the
greater the risk of late onset cardiotoxicity. Up to 65% of children ex-
posed to doxorubicin experience some type cardiac dysfunction at
least one year after treatment [56].4. Cardiac remodeling
In humans, depression of fractional shortening and ejection fraction
are the hallmarks for doxorubicin induced degradation of cardiac func-
tion. Similar results in animal studies indicate their value as suitable
surrogates for the human condition [67,68]. The early effects of
doxorubicin-induced cardiotoxicity may also be attributed to altered
Ca+2 dynamics, increased oxidative stress, and altered myocardial
energetics [23,26,67,68].
Acutely, a single dose of doxorubicin has been shown to impairmyo-
cardial contractility. Doxorubicin-induced cardiomyopathy produces
cytoplasmic vacuolation, swelling of the sarcoplasmic reticulum, and
myoﬁbrillar disarray [11,12,39,40,71]. Using endomyocardial biopsies
from patients receiving doxorubicin, Billingham et al. observed focal le-
sions but without inﬂammatory inﬁltrate being present [9]. All patients
receiving more than 240 mg/mm2 had evidence of degeneration, and
presented initially with a loss of myoﬁbrillar elements or vacuolar de-
generation. In a separate study using daunorubicin, although morpho-
logic disarrangements were observed in both chambers, the RV had a
milder presentation [52]. Consistent with this, expression of sarcomeric
proteins was impaired in the LV but not the RV. Following a single dose
of 6.0 mg/kg of doxorubicin in rats, the maximal contractile force was
12% lower than controls after one week [67]. Parallel ﬁndings were
observed in another study; cardiac actomyosin ATPase activity was
decreased and this decrease was dose dependent [9]. The heart does at-
tempt to compensate andmaximal contractility recovered transiently to
normal values three weeks after treatment, but then declined to 40%
after eight weeks [67].
As a cytotoxic agent, doxorubicin diminishes the ability of tumor
cells to breakdown the extracellular matrix, impairing cell mobility
[71]. This would suggest that altered extracellular matrix within the
heart should also be altered leading to compromised function and
such an outcome might be reﬂected as altered diastolic dysfunction.
Several cohort studies have reported diastolic and diastolic plus systolic
dysfunction as an outcome of doxorubicin treatments in different pa-
tient population including children [16,81,111]. Ivanová et al. and
others have demonstrated that mRNA and protein levels of several ma-
trix metalloproteinases were signiﬁcantly increased in cardiomyocytes
bydoxorubicin [3,38]. These enzymes are signiﬁcant in that they disrupt
the integrity of the ﬁbrillar collagen network resulting in left ventricular
pump dysfunction. Consistent with this, decreases in the inhibitor of
metalloproteinase-1 were observed following doxorubicin treatment
[34]. Rescue experiments that inhibitedmatrix metalloproteinase activ-
ity have beenused to show improved left ventricular pump function fol-
lowing doxorubicin treatment [20,86]. These ﬁndings suggest the
participation of the matrix metalloproteinases in the progression ofdoxorubicin induced heart failure by promoting myocardial extracellu-
lar remodeling.
5. Cardiomyopathy: molecular mechanisms
Doxorubicin operates on many levels by different mechanisms in-
cluding an interaction with iron, altering the activity of intracellular or
intra-mitochondrial oxidant enzymes, and binding to topoisomerases.
Problematic in their study is themyriad of secondary pathways activated
by these primary effects.
6. Free radicals and iron
The second major pathway of cell toxicity is doxorubicin induced
increases in intracellular radial oxygen species. The early-onset cardio-
myopathy seen after treatment with doxorubicin is thought in part to
be induced by oxidative stress and mitochondrial dysfunction in
cardiomyocytes. Different pathways are thought responsible for doxo-
rubicin induced oxidant stress. Doxorubicin may cause oxidative stress
by interacting directly with iron after being reduced by NADPH-
cytochrome P450 reductase to yield a doxorubicin semiquinone. This
reduced form of doxorubicin can complex with Fe+2. The free radical
complex can spontaneously reduce oxygen to superoxide, resulting in
the regeneration of doxorubicin and the cycle can begin again. Free
oxygen radicals are also produced when doxorubicin gets reduced at
Complex I of the electron transport chain. This semiquinone can reduce
oxygen to generate increased levels of superoxide and other reactive
oxygen species in mitochondria, leading to dysfunction. Semiquinones
of doxorubicin aglycones at Complex I have also been shown to yield in-
creased production of hydroxyl radicals, contributing to mitochondrial
oxidative stress. Given the high dependence of cardiomyocytes on
aerobic metabolism, cardiotoxicity may not be surprising outcome.
Doxorubicin has been shown to bind to nitric oxide synthase
through a direct interaction with the enzyme [45]. This promotes
monomerization of the enzyme which shifts the reaction mechanism
to favor the production of superoxide rather than nitric oxide. And
with greater concentrations of superoxide, interaction of the reactive
oxygen species with nitric oxide becomes more likely. This reaction
yields an extremely potent free radical, peroxynitrite. This free radical
can cross lipid membranes, enabling it to enter the nucleus and mito-
chondria, potentiating the deleterious effects of oxidative stress on
cardiomyocytes.
A third pathway for doxorubicin is to bemetabolized to doxorubicinol,
a metabolite thought to interfere with a key iron regulator protein,
aconitase-1. This interaction with aconitase-1 releases free iron concen-
trations to the cell preventing the translation of ferritin, an iron-
sequestering protein, and inhibiting the breakdown of the transferrin re-
ceptor, which allows more iron to enter the cell [8]. Transition metals,
such as iron, are known to catalyze the production of free radicals, thus
doxorubicinol secondarily contributes to the oxidative stress seen in
cells. This contribution is supported by observations that doxorubicin-
induced cardiotoxicity was increased in iron-loaded rats [73].
Studies using iron chelators have demonstrated variable effects on
doxorubicin mediated cardiotoxicity. Deferoxamine appeared to offer
no protective effects to doxorubicin induced cardiotoxicity [83]. In con-
trast, dexrazoxane (Zinecard) is an FDA approved drug approved for
cardioprotection. Dexrazoxane can enter the cell, where it is metabo-
lized into its open-ring form, ADR-925. The open-ring structure resem-
bles the iron chelator EDTA, and can bind free iron in the cell, decreasing
intracellular concentrations or can disrupt the association of iron with
doxorubicin, preventing the doxorubicin-iron complex from forming,
thereby decreasing superoxide production. Dexrazoxane's protective
effects appear in part to be that of protecting the cardiac mitochondria.
Lebrecht et al. demonstrated that cardiomyocytes from rats treatedwith
doxorubicin and dexrazoxane for seven weeks had greater mitochon-
drial function than rats treated with doxorubicin alone [50]. These
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due to other mechanisms in addition to sequestering iron within the
cell.
Other evidence also questions howcritical the role of iron and reactive
oxygen species are in doxorubicin-induced cardiotoxicity. Administration
of antioxidants, such asN-acetylcysteine and polyphenols attenuated ap-
optosis in vitro or short-term animal experiments. However no signiﬁ-
cant improvement in doxorubicin-induced cardiotoxicity was observed
when studied in long-term animal experiments or in clinical trials [83].
The inconclusive data on iron chelators and antioxidants creates doubt
about the classic deﬁnition of oxidant stress in cardiotoxicity [83]. It
does point towards experimentation the use of mitochondrial-directed
antioxidants to differentiate the respective roles of cytoplasmic versus
mitochondrial derive ROS.
7. Topoisomerase II
Although the oxidant role of doxorubicin was originally thought to
be singular, it has become evident that doxorubicin's interaction with
topoisomerases is of primary importance. Topoisomerases are highly
conserved proteins present in all organisms. Humans have seven
topoisomerases that may be divided into three classes; type IA, IB, and
II. Topoisomerases resolve the topological difﬁculties of DNA replication
by allowing the double helix to pass through itself. This entails a com-
plex reaction order where 1) DNA is bound, 2) double DNA strand
breaks are induced, 3) the DNA structure is rotated to relieve torsion-
induced stress, and 4) religation of DNA strands. At least six isoforms
of topoisomerase are present in the nucleus and mitochondria of the
cardiomyocyte [58,104,108]. Other isoforms are present in other cell
populations within the heart. Topoisomerase type IIs differ from
topoisomerase type I which induce only single DNA strand breaks to re-
lieve torsional stress. Topoisomerases II form double strand DNA breaks
are the most lethal form of DNA damage [41]. Although topoisomerase
activity is essential to the cell and generally protective, they may also
be genotoxic [25,30].
Topoisomerases are enzymes and several post-translational modiﬁ-
cations exist that modulate function including myristoylation,
palmitoylation, sumoylation and phosphorylation [60,62]. Both protein
kinase C and casein kinase I δ/ε activities have shown to modulate DNA
cleavage activity of topoisomerase IIα [35,107]. Dephosphorylation de-
presses topoisomerase relaxation of supercoiled (SC) DNA [87]. Further
it has been suggested that oxidative stress alters nuclear topoisomerase
function to stabilize the topoisomerase/DNA complex while inhibiting
the religation process leading to an increase in DNA strand breakage
[53]. Whether this is in fact the underlying mechanism of doxorubicin-
induced oxidant stress remains to be determined.
Within the heart topoisomerase II proteins are found as two nuclear
localized isoforms IIα and IIβ and one mitochondrial IIβ isoform.
Doxorubicin is a topoisomerase inhibitor that intercalates with DNA to
block progression of topoisomerase II and it binds equally to topoisom-
erase IIα and IIβ [95]. Doxorubicin interacts with topoisomerase and
DNA to form a DNA cleavage complex that increases double strand
breakage; this serving as its underlying use as a cytotoxic reagent.
Zhang et al. hypothesized that acute doxorubicin cardiomyocyte
toxicity may be due to the capability of doxorubicin to interact with
topoisomerase IIβ. Their ideaswere supported from studies using a car-
diomyocyte knockout of topoisomerase IIβ in mice. While doxorubicin
treatment decreased ejection fraction 10% in normal animals, it had no
effect on cardiovascular function in the knockout animals [109]. This
work has refocused drug development towards drugs which are protec-
tive. The FDA approved drug dexrazoxane (Zinecard) is foremost used
for cardioprotection from doxorubicin. Although originally thought to
be only an iron chelator (see below) it may compete with topoisomer-
ase II as well as act to deplete topoisomerase II expression [24,106].
Alternative approaches towards cardioprotection have been to de-
sign drugs that only target topoisomerase IIα that is not normallypresent within the cardiomyocytes [19]. Surprisingly, salicylate an ac-
tive metabolite of acetylsalicylic acid (aspirin) has been reported as an
inhibitor of topoisomerase IIα and should in theory be protective of
the myocardium [6]. While as anti-cancer drugs this approach holds a
great deal of promise, it is not without some drawbacks. It has become
apparent over the last decade that the heart is not a static organ and
that continual cell replacement from cardiac progenitor cells serves to
renew the cardiomyocytes of the heart. Malignant cells and undifferen-
tiated cells (including cardiac progenitor cells) uniquely express topo-
isomerase IIα, while cardiomyocytes and other differentiated cells
express topoisomerase IIβ. Thus while deletion of topoisomerase IIβ
may be protective of the cardiomyocytes, the long term consequence
of doxorubicin treatment on cardiac progenitor cells remains unclear.
8. Calcium dysregulation
Loss of calcium homeostasis is another effect of doxorubicin.
Doxorubicinol has been demonstrated to interferewith calcium seques-
tration by the sarcoplasmic reticulum by altering the calcium pump,
SERCA, found on its membrane [69]. The sodium/potassium pump of
the sarcolemma is also affected by doxorubicinol, which disrupts the
sodium gradient needed for calcium to ﬂow into the sarcolemma of a
cardiomyocyte. Doxorubicinol may also interact with the ryanodine re-
ceptor, allowing an uncontrolled ﬂow of calciumout of the sarcoplasmic
reticulum. Further, doxorubicin has been shown to decrease the calcium
storage capacity of mitochondria by speciﬁcally activating the selective
CsA-sensitive calcium channel, exacerbating the calciumoverload [110].
Disruption of these pumps and channels alters calcium homeostasis,
which also leads to mitochondrial dysfunction and apoptosis. Zhou
et al. demonstrated that mitochondria from doxorubicin treated hearts
had a signiﬁcantly lower calcium-loading capacity. Fiveweeks after ces-
sation of treatment, the ability of the mitochondria to store calcium still
did not improve, suggesting that these effects cannot be reversed after
treatment, suggesting that these effects are both cumulative and irre-
versible [110]. Verapamil blocks L-type calciumchannels andmay effec-
tively decreases the calcium overload caused by doxorubicin [77].
However, some studies have demonstrated that administering doxoru-
bicin and verapamil in conjunction actually further potentiates
cardiotoxicity. The mechanism behind these results remains controver-
sial, but the hypothesis that verapamil overload itself has cardiotoxic
effects, separate from doxorubicin [1,79]. Muscle contraction is
calcium-dependent and lowering intracellular calcium within
cardiomyocytes would result in decreased contractility, suggesting a
ﬁne balance between usefulness and detriment.
9. Mitochondrial dysfunction
Doxorubicin accumulates in the nucleus and the mitochondria [69].
Similar to the nucleus, the mitochondria contains topoisomerase 2β, a
speciﬁc target of doxorubicin. The functional role of mitochondrial
topoisomerase II® remains unclear, however it has been suggested to
participate in decatenating newly synthesized mtDNA circles [58].
Within the mitochondria, single strand DNA nicks also act to localize
topoisomerases to the mtDNA and induce cleavage on the opposite
strand [25,46]. This would not only enhance DNA cleavage by
topoisomerases in the mitochondria but would also hold mtDNA “in
an open conformation” longer and expose it to further ROS attack. All
of these avenues serve to interfere with mitochondrial replication and
transcription causing signiﬁcant imbalances in the stoichiometry of
the Electron Transport Chain and promoting dysfunction. Doxorubicin
may also promote apoptosis by localizing to themitochondria and stim-
ulating the release of cytochrome C [97]. Secondarily, the drug inducted
oxidative stress and abnormally high levels of calcium within the cell,
both of which are known to stimulate the release of cytochrome C and
initiate apoptotic pathways through caspase activation [71]. Derivatives
of doxorubicin also promote cytochrome C release by accumulating in
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chain [97]. Contrary to these ideas is evidence for an increase in the
Bcl2:Bax ratio as a function of a decline in Bax, a shift which is
antiapoptotic. This is possibility of the induction of a compensatory pro-
tective response againstmitochondrial-mediated apoptosis, providing a
mechanism for how cardiomyocytes are able to survive exposure to the
drug. Overexpression of various antioxidant enzymes, such as manga-
nese superoxide dismutase and catalase, along with increased mito-
chondrial efﬁciency were also seen after treatment with doxorubicin,
supporting the existence of a compensatory response [20].
10. Endothelin-1
Alteration of endothelin-1 expression in cardiomyocytes seen after
treatment with doxorubicin provides an additional mechanism of
cardiotoxicity. Endothelin-1 modulates the IP3 pathway in cardio-
myocytes, causing increased release of calcium from the sarcoplasmic re-
ticulum and is thus stimulates contraction. After treatment with
doxorubicin, mRNA and plasma levels of endothelin-1 in mice are signif-
icantly increased [10]. This increase in endothelin-1 caused by doxorubi-
cin potentiates the increased calcium load in cardiomyocytes, thereby
facilitating apoptosis and cardiac dysfunction. Clinically, patients with
doxorubicin-induced congestive heart failure also have increased levels
of endothelin-1. Although up regulation of endothelin-1 normally pro-
motes cell survival by affecting cell signaling in the heart, the vasocon-
strictive properties of this molecule in the vasculature are deleterious in
doxorubicin treated patients. Normally, vasodilatation induced by nitric
oxide can counteract the potent constriction caused by endothelin-1,
however, as explained earlier, doxorubicin modulates the nitric oxide
system. This disables endothelial cells from responding appropriately to
the vasoconstriction, which facilitates the progression of hypertension
and can lead to heart failure. The role of doxorubicin-induced changes
on endothelin-1 and subsequent cardiomyopathy is supported by the im-
provement in cardiac function observed after administration with antag-
onists of the endothelin-1 receptor or inhibition of endothelin-converting
enzyme-1.
After demonstrating doxorubicin-induced up regulation of
endothelin-1 and cardiac dysfunction, Bien et al., showed that pretreat-
mentwith bosentan, an antagonist of the endothelin B receptor, resulted
in marked increased systolic, diastolic, and left ventricular function as
compared to mice treated only with doxorubicin [10]. Mice pretreated
with the antagonist had increased stroke volume, ejection fraction, and
cardiac output in addition to decreased myocardial stiffness, suggesting
that endothelin-1 signaling plays a critical role doxorubicin-induced car-
diac dysfunction. Further, mice treated with bosentan had decreased
levels of tumor necrosis factor-(TNF), a factor known to stimulate tran-
scription of proapoptotic proteins such as Bax. Mice that received pre-
treatment also had decreased Bax levels, providing evidence that
blocking endothelin-1 may also participate in blocking apoptosis in
cardiomyocytes, which could contribute to the improvement in cardiac
function seen in these animals.
Additionally, similar results were also seen in endothelin-converting
enzyme-1 heterozygous knockouts treated with doxorubicin, especially
in regard to lipid peroxidation and mitochondrial damage [66]. Not only
did endothelin-converting enzyme-1 heterozygotes have improved car-
diac function compared to wild type after treatment with doxorubicin,
but there was also preservation of mitochondrial activity. Heterozygotes
treatedwith doxorubicin had higher ATP levels thanwild types receiving
treatment, suggestingmaintenance ofmitochondrial functionwas associ-
ated with decreased levels of endothelin-1. Increased expression of su-
peroxide dismutase along with decreased cardiac lipid peroxidation
was also seen in these animals, providing evidence that endothelin-1
may participate in the oxidative stress caused by doxorubicin. Further,
mitochondrial biogenesis also seemed to be preserved in the heterozy-
gotemice, demonstrated by the normal levels of a key transcription factor
involved in mitochondrial biogenesis, peroxisome proliferator-activatedreceptor-γ coactivator 1α (PGC-1 α). Transcription of this factor is
inhibited by doxorubicin; however decreased levels of PGC-1 α were
not seen in the knockout animals, supporting the critical role of
endothelin-1 in doxorubicin-induced mitochondrial dysfunction. Collec-
tively, these data suggest that endothelin-1 facilitates this type of cardio-
myopathy and may provide insight about potential preventative
treatments for this toxicity.
11. Treatment and prevention of cardiotoxicity
Doxorubicin is an effective chemotherapeutic agent and treatments
that would protect patients from acute and chronic cardiotoxicity with-
out altering cytotoxicity of abnormal cellswould be the ideal goal for the
management of cancer patients. Several cardioprotective agents have
been explored in the treatment and prevention of doxorubicin-
induced cardiomyopathy, including drugs that directly interfere with
the cellular mechanisms of doxorubicin or are used in the traditional
management of heart failure.
Dexrazoxane appears to be the most efﬁcacious drug tested to date.
Aside from directly competing with topoisomerase II, it can diminish
oxidative stress in cardiomyocytes caused by the interaction of doxoru-
bicin and iron, and may also stimulate expression of mitochondrial an-
tioxidant enzymes. Based on these properties, dexrazoxane, also
known as Zinecard ☐ (Pﬁzer Pharmaceuticals, New York, NY), has
been recognized as a cardioprotective agent when administered in con-
junction with doxorubicin and is now the mostly commonly used
protocol.
Not perfect but good, it has been suggested in some studies that
dexrazoxane may diminish the antineoplastic actions of doxorubicin
when administered in conjunction. Others have depicted lower re-
sponse rates and even occurrences of secondary malignancies after
treatment with both drugs [96]. Barry et al. did not observe an associa-
tion of dexrazoxane treatmentwith appearance of secondarymalignant
neoplasms [4]. In instances where a patient's cumulative dose of doxo-
rubicin exceeded 300 mg/m2, such as in treatment of advanced meta-
static breast cancer, dexrazoxane treatment did signiﬁcantly lower
incidence of congestive heart failure with little effect on time to cancer
progression [92,93].
Some traditional treatments for heart failure may also be
cardioprotective in patients treatedwith doxorubicin. Carvedilol, a non-
speciﬁc inhibitor of adrenergic receptors, has demonstrated a protective
role. Carvedilol has also been shown to have antioxidant properties as
well as protect against calcium dysregulation by blocking the
doxorubicin-induced down-regulation of sarcoplasmic reticular calci-
um pumps [44]. From preclinical studies, carvedilol was shown to re-
duce the histological evidence of cardiomyopathy and reduce changes
in left ventricular ejection fraction when administered in combination
with doxorubicin [61]. Subsequent clinical trials yielded similar out-
comes, patients given carvedilol in conjunction with doxorubicin had
no signiﬁcant changes in left ventricular ejection fraction, whereas pa-
tients treated with doxorubicin alone had a signiﬁcant decrease of
about 24% [44]. In children with acute lymphoblastic leukemia that
were treated with carvedilol in combination with doxorubicin found a
similar efﬁcacy of carvedilol in preventing cardiac dysfunction in chil-
dren compared to studies conducted on adults [27].
Other compounds that show somepromise include antioxidants such
as ﬂavonoids or probucol. The ﬂavonoid, monohydroxyethylrutoside
(monoHER), is currently being investigated in clinical trials. In preclinical
studies, monoHER was administered to nude mice with human tumor
xenografts in conjunction with doxorubicin [5]. They found that near
term effects of doxorubicin on cardiovascular function were depressed
while monoHER did not appear to alter antitumor activity. In a phase 1
study, in healthy volunteers received monoHER doses up to
1500 mg/m2 was found to be feasible [105]. Unfortunately when
moved to a phase II trial with patients withmetastatic cancer, monoHER
did not appear to be cardioprotective and the authors suggested that the
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antioxidant previously used to treat various cardiovascular diseases
remains in preclinical studies,where it has been shown to offer protection
against doxorubicin induced cardiotoxicity [49,84]. More recently,
phosphodiesterase-5 inhibitors, such as sildenaﬁl, have demonstrated
cardioprotective effectswhenadministeredprophylactically [22,48]. Fish-
er et al. (2005) administered doxorubicin or doxorubicin and sildenaﬁl to
mice for two weeks and subsequent measures of cardiac function and
levels of apoptosis were measured over the course of ten weeks [29].
Whereasmice treatedwith only doxorubicin had a signiﬁcantly increased
apoptotic index, those treated with doxorubicin and sildenaﬁl did not.
Another example of application of a pre-existing drug to the doxoru-
bicin induced cardiotoxicity model is rimonabant. The cannabinoid-1
receptor antagonist is approved in Europe as a weight loss drug for
obese patients at high risk for other diseases such as type II diabetes
and dyslipidemia [102]. Its potential is unclear since stimulation of the
cannabinoid-1 receptor in the heart is cardiodepressive and it is un-
known if rimonabant interactswith doxorubicin or having a positive in-
ﬂuence by blocking the cannabinoid-1 receptor [13]. The results from
one preclinical study suggested that rimonabant may counter some
cardiotoxic pathways of doxorubicin. Mice treated with doxorubicin
alone had signiﬁcantly decreased cardiac function, shown by decreased
strokework, ejection fraction, cardiac output, and left ventricular systol-
ic pressure, as compared to control mice that received a vehicle or
rimonabant alone. In contrast, animals that received both doxorubicin
and rimonabant demonstrated signiﬁcantly increased cardiac function
compared to those that received doxorubicin alone. However, the mea-
surements of cardiac function in themice treated with both drugs were
still signiﬁcantly lower than the control animals suggesting a need for
further work [68]. Although promising, to date these preclinical studies
have only examined short term outcomes.12. Conclusions
Doxorubicin is a potent chemotherapeutic agent used to treat a vari-
ety of cancers. The chemical structure of the drug facilitates its cytotox-
icity, allowing it to enter many intracellular compartments, including
the nucleus and mitochondria. It is administered intravenously as a hy-
drochloride salt by various dose schedules in cancer patients. The efﬁca-
cy of doxorubicin as a cancer treatment is attributed to the various
cytotoxic mechanisms by which it acts, most notably by inducing DNA
damage through interaction with topoisomerase II and production of
free radicals through interaction with intracellular oxidoreductases.
However, these actions of the drug also result in various hematological
and gastrointestinal toxicities.
Several factors are associated with increased risk of developing
cardiotoxicity after doxorubicin treatment, with increased cumulative
dose being the greatest risk. Additionally, treatments with other
cardiotoxic agents, radiation therapy, or preexisting cardiac conditions
exacerbate this risk. Pediatric cancer patients exposed to the drug at a
young age also have an increased risk of developing late-onset
cardiotoxicity, although the under causes remain unclear.
Because doxorubicin is an effective cancer treatment, methods to
prevent the cardiotoxicity have long been sought. Monitoring
cardiotoxicity through various markers helps prevent progression to
fatal congestive heart failure. Standard tests of cardiac function are
often used to assess doxorubicin-induced toxicity, however certain
methods have proven to better detect the early signs of cardiac injury.
Although electrocardiography and echocardiography can provide useful
information, radionuclide tests are currently themost reliable and accu-
ratemethod for detection of cardiac dysfunction in patients treatedwith
doxorubicin. Two-dimensional radial strain echocardiography is a
newer technique that has been demonstrated to detect cardiac injury
at an even earlier stage, making it an extremely valuable tool. Histolog-
ical tests and scintigraphy are both sensitive to early cardiomyopathy;however these invasive techniques are less practical because of the in-
creased risks they pose to the patient.
Drugs that can treat or prevent doxorubicin-induced cardiotoxicity
would be extremely helpful for patients that have been treated with
doxorubicin in the past or who have cancer that is effectively treated
by doxorubicin. Several drugs are being investigated, with dexrazoxane
(Zinecard™) being the most effective preventative treatment at this
time. Other drugs under current investigation are ﬂavonoids such as
monoHER and carvedilol, a non-speciﬁc adrenergic receptor inhibitor.
Many drugs approved for treatment of other diseases are also being
evaluated for their efﬁcacy in preventing doxorubicin-induced cardio-
myopathy. These drugs include sildenaﬁl, a phosphodiesterase-5 inhibi-
tor, probucol, an antioxidant, and rimonabant, a cannabinoid-1 receptor
antagonist. Animal studies provide evidence for the cardioprotective
properties of these agents, but these studies are limited in only examin-
ing the short term consequences and little is known about their potential
protective role for late onset cardiac dysfunction.
Doxorubicin is a drug that effectively treats one fatal disease, but its
severe side effects can also be fatal. Identiﬁcation ofmethods to success-
fully ameliorate these toxicities through preventative or alternative
treatments would have a great impact on clinical oncology.
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